BR112012006103B8 - dispositivo de implante e kit - Google Patents

dispositivo de implante e kit

Info

Publication number
BR112012006103B8
BR112012006103B8 BR112012006103A BR112012006103A BR112012006103B8 BR 112012006103 B8 BR112012006103 B8 BR 112012006103B8 BR 112012006103 A BR112012006103 A BR 112012006103A BR 112012006103 A BR112012006103 A BR 112012006103A BR 112012006103 B8 BR112012006103 B8 BR 112012006103B8
Authority
BR
Brazil
Prior art keywords
implant devices
implant
methods
another aspect
bioactive agent
Prior art date
Application number
BR112012006103A
Other languages
English (en)
Other versions
BR112012006103A8 (pt
BR112012006103A2 (pt
BR112012006103B1 (pt
Inventor
W Hudson Bruce
Markland Peter
Original Assignee
Evonik Corp
Evonik Degussa Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Evonik Corp, Evonik Degussa Corp filed Critical Evonik Corp
Publication of BR112012006103A2 publication Critical patent/BR112012006103A2/pt
Publication of BR112012006103A8 publication Critical patent/BR112012006103A8/pt
Publication of BR112012006103B1 publication Critical patent/BR112012006103B1/pt
Publication of BR112012006103B8 publication Critical patent/BR112012006103B8/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A61K9/0024—Solid, semi-solid or solidifying implants, which are implanted or injected in body tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/08—Peptides having 5 to 11 amino acids
    • A61K38/09—Luteinising hormone-releasing hormone [LHRH], i.e. Gonadotropin-releasing hormone [GnRH]; Related peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/146—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5084—Mixtures of one or more drugs in different galenical forms, at least one of which being granules, microcapsules or (coated) microparticles according to A61K9/16 or A61K9/50, e.g. for obtaining a specific release pattern or for combining different drugs

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Endocrinology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Reproductive Health (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Dermatology (AREA)
  • Inorganic Chemistry (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

dispositivos de implante que diferem pelo perfil de liberação e métodos de fabricação e utilização dos mesmos. a invenção se refere a dispositivos de implante, aos kits que compreendam os dispositivos de implante, e a métodos de fabricação e utilização dos dispositivos e kits. em um aspecto, uma pluralidade de dispositivos de implante compreende, pelo menos, dois implantes que apresentam um perfil de liberação diferente de um agente bioativo. em outro aspecto, o dispositivo de implante compreende um ou mais corpos de polímero unidos em que, pelo menos, dois dos corpos do polímero apresentam um perfil de liberação diferente de um agente bioativo. em outro aspecto, o kit compreende um ou mais dispositivos de implante apresentados. em outro aspecto, os métodos de administração de um agente bioativo em um paciente compreendem a administração no paciente de um ou mais dispositivos de implante apresentados.
BR112012006103A 2009-09-17 2010-09-16 dispositivo de implante e kit BR112012006103B8 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US24330309P 2009-09-17 2009-09-17
US61/243,303 2009-09-17
PCT/US2010/049104 WO2011035013A2 (en) 2009-09-17 2010-09-16 Implant devices that differ by release profile and methods of making and using same

Publications (4)

Publication Number Publication Date
BR112012006103A2 BR112012006103A2 (pt) 2016-06-07
BR112012006103A8 BR112012006103A8 (pt) 2017-10-03
BR112012006103B1 BR112012006103B1 (pt) 2020-10-27
BR112012006103B8 true BR112012006103B8 (pt) 2021-05-25

Family

ID=43218276

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112012006103A BR112012006103B8 (pt) 2009-09-17 2010-09-16 dispositivo de implante e kit

Country Status (10)

Country Link
US (1) US9399018B2 (pt)
EP (1) EP2477612A2 (pt)
JP (1) JP2013505251A (pt)
KR (1) KR20120102598A (pt)
CN (1) CN102917693B (pt)
BR (1) BR112012006103B8 (pt)
CA (1) CA2774495C (pt)
IN (1) IN2012DN02656A (pt)
RU (1) RU2012115120A (pt)
WO (1) WO2011035013A2 (pt)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2432556T3 (es) 2004-08-04 2013-12-04 Evonik Corporation Métodos para fabricar dispositivos de suministro y sus dispositivos
US20110091518A1 (en) * 2009-09-22 2011-04-21 Danielle Biggs Implant devices having varying bioactive agent loading configurations
WO2018064544A1 (en) 2016-09-29 2018-04-05 Gesea Biosciences Inc. Bioerodible contraceptive implant and methods of use thereof
KR102183669B1 (ko) * 2019-03-26 2020-11-26 가톨릭대학교 산학협력단 이중 약물 방출을 위한 약물 전달체
JP6905035B2 (ja) * 2019-11-29 2021-07-21 Ｎｉｓｓｈａ株式会社 可食性フィルムの製造方法、フィルム製剤及び可食性フィルム

Family Cites Families (42)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6309669B1 (en) * 1984-03-16 2001-10-30 The United States Of America As Represented By The Secretary Of The Army Therapeutic treatment and prevention of infections with a bioactive materials encapsulated within a biodegradable-biocompatible polymeric matrix
US4720384A (en) * 1985-05-03 1988-01-19 E. I. Du Pont De Nemours And Company Manufacture of hollow fine tubular drug delivery systems
US4976949A (en) * 1985-10-25 1990-12-11 The University Of Michigan Controlled release dosage form
US4794001A (en) * 1986-03-04 1988-12-27 American Home Products Corporation Formulations providing three distinct releases
JPS63203610A (ja) * 1987-02-12 1988-08-23 ヘキスト・アクチエンゲゼルシヤフト 複数成分からなるインプラント用の持効性医薬製剤
DE3710175A1 (de) * 1987-02-12 1988-08-25 Hoechst Ag Mehrteilige implantierbare arzneizubereitung mit langzeitwirkung
US4897268A (en) * 1987-08-03 1990-01-30 Southern Research Institute Drug delivery system and method of making the same
US5035891A (en) * 1987-10-05 1991-07-30 Syntex (U.S.A.) Inc. Controlled release subcutaneous implant
JP2702729B2 (ja) * 1988-02-24 1998-01-26 エーザイ株式会社 徐放性埋込剤
US5702716A (en) * 1988-10-03 1997-12-30 Atrix Laboratories, Inc. Polymeric compositions useful as controlled release implants
US5178874A (en) * 1989-06-30 1993-01-12 Smithkline Beechman Corporation Intermittent release dosage form
US5153002A (en) * 1991-03-04 1992-10-06 University Of Montreal Biocompatible gradient controlled release implant
JP3118009B2 (ja) 1991-04-16 2000-12-18 住友製薬株式会社 多層構造を有するコラーゲンおよび／またはゼラチン製剤の製造方法
US5876452A (en) * 1992-02-14 1999-03-02 Board Of Regents, University Of Texas System Biodegradable implant
US6013853A (en) * 1992-02-14 2000-01-11 The University Of Texas System Continuous release polymeric implant carrier
US5429822A (en) * 1992-03-13 1995-07-04 Cambridge Scientific, Inc. Biodegradable bursting release system
GB9223144D0 (en) * 1992-11-05 1992-12-16 Scherer Corp R P Controlled release device
US5456917A (en) * 1993-04-12 1995-10-10 Cambridge Scientific, Inc. Method for making a bioerodible material for the sustained release of a medicament and the material made from the method
US6447796B1 (en) * 1994-05-16 2002-09-10 The United States Of America As Represented By The Secretary Of The Army Sustained release hydrophobic bioactive PLGA microspheres
US6855331B2 (en) * 1994-05-16 2005-02-15 The United States Of America As Represented By The Secretary Of The Army Sustained release hydrophobic bioactive PLGA microspheres
US5958458A (en) * 1994-06-15 1999-09-28 Dumex-Alpharma A/S Pharmaceutical multiple unit particulate formulation in the form of coated cores
US6902743B1 (en) * 1995-05-22 2005-06-07 The United States Of America As Represented By The Secretary Of The Army Therapeutic treatment and prevention of infections with a bioactive material(s) encapuslated within a biodegradable-bio-compatable polymeric matrix
US5705191A (en) * 1995-08-18 1998-01-06 The United States Of America As Represented By The Secretary Of The Navy Sustained delivery of active compounds from tubules, with rational control
EP1001743B1 (fr) * 1997-06-04 2006-02-01 Debio Recherche Pharmaceutique S.A. Implants pour la liberation controlee de principes pharmaceutiquement actifs et procede pour leur fabrication
US6599529B1 (en) * 1997-09-11 2003-07-29 Nycomed Danmark A/S Modified release multiple-units compositions of non-steroid anti-inflammatory drug substances (NSAIDs)
US6296831B1 (en) * 1998-04-10 2001-10-02 Battelle Memorial Institute Stimulus sensitive gel with radioisotope and methods of making
DE69940735D1 (de) * 1998-07-17 2009-05-28 Pacira Pharmaceuticals Inc Biologisch abbaubare anordnungen zur kontrollierten freigabe eingeschlossener substanzen
US6248363B1 (en) * 1999-11-23 2001-06-19 Lipocine, Inc. Solid carriers for improved delivery of active ingredients in pharmaceutical compositions
WO2001007079A1 (en) * 1999-07-26 2001-02-01 Bomac Laboratories Limited Improvements in dispensing vaccines
US20020131988A1 (en) * 1999-12-16 2002-09-19 Foster Todd P. Pharmaceutical implant containing immediate-release and sustained-release components and method of administration
IL150657A0 (en) * 2000-01-20 2003-02-12 Delsys Pharmaceutical Corp Multi-step drug dosage forms
US6479065B2 (en) * 2000-08-10 2002-11-12 Alkermes Controlled Therapeutics, Inc. Process for the preparation of polymer-based sustained release compositions
US20030055075A1 (en) 2001-07-13 2003-03-20 Rubsamen Reid M. Programmable controlled release injectable opioid formulation
NZ519363A (en) * 2002-06-05 2004-02-27 Agres Ltd A novel drug dosing regimen
US7101566B2 (en) 2002-06-28 2006-09-05 Ethicon, Inc. Polymer coated microparticles for sustained release
US7220433B2 (en) * 2003-06-27 2007-05-22 Ethicon, Inc. Compositions for parenteral administration and sustained-release of therapeutic agents
US8329203B2 (en) * 2004-01-12 2012-12-11 The Trustees Of The University Of Pennsylvania Drug-containing implants and methods of use thereof
US8685435B2 (en) * 2004-04-30 2014-04-01 Allergan, Inc. Extended release biodegradable ocular implants
WO2005107715A1 (en) * 2004-05-11 2005-11-17 Debio Recherche Pharmaceutique S.A. Implantable composition
ES2432556T3 (es) 2004-08-04 2013-12-04 Evonik Corporation Métodos para fabricar dispositivos de suministro y sus dispositivos
WO2006071208A1 (en) * 2004-12-23 2006-07-06 Durect Corporation Polymeric implants, preferably containing a mixture of peg and plg, for controlled release of a gnrh
US8969415B2 (en) * 2006-12-01 2015-03-03 Allergan, Inc. Intraocular drug delivery systems

Also Published As

Publication number Publication date
JP2013505251A (ja) 2013-02-14
CN102917693A (zh) 2013-02-06
EP2477612A2 (en) 2012-07-25
BR112012006103A8 (pt) 2017-10-03
CN102917693B (zh) 2015-05-20
BR112012006103A2 (pt) 2016-06-07
KR20120102598A (ko) 2012-09-18
CA2774495A1 (en) 2011-03-24
WO2011035013A2 (en) 2011-03-24
BR112012006103B1 (pt) 2020-10-27
CA2774495C (en) 2017-09-26
US20110142906A1 (en) 2011-06-16
US9399018B2 (en) 2016-07-26
RU2012115120A (ru) 2013-10-27
WO2011035013A3 (en) 2011-12-29
IN2012DN02656A (pt) 2015-09-11

Similar Documents

Publication Publication Date Title
MX2015015772A (es) Implante quirurgico que comprende una capa que tiene aberturas.
PA8770101A1 (es) Amidas de 4-aril-1,4-dihidro-1, 6-naftiridina sustituidas y su uso
BRPI0917920B8 (pt) expansão direcional de dispositivos intraluminais
CR11731A (es) Composiciones y procedimientos para su preparación y uso
ATE502658T1 (de) Polymer-komposit-stent mit polymerteilchen
BR112017001456A2 (pt) sistemas de prótese provisória e métodos de utilização dos mesmos
CL2008000219A1 (es) Composicion farmaceutica de liberacion modificada que comprende a uno o mas ingredientes farmaceuticamente activos, con solubilidad dependiente del ph, un polimero controlador de la liberacion, agentes facilitadores de la gelificacion; procedimiento
BRPI0817437A2 (pt) Implante cirúrgico com um recurso antirretrocesso
BRPI0811845A2 (pt) Forma de dosagem, e, métodos de preparação da forma de dosagem, e de tratamento de uma má condição em um paciente
ATE481990T1 (de) Implantierbare medizinprodukte aus verzweigten polymeren
BR112012001372A2 (pt) comprimido, e, métodos para preparar um comprimido e para a profilaxia ou tratamento de hiperfosfatemia.
EA201400119A1 (ru) Фармацевтическая композиция, способы лечения и их применение
BRPI0815703A2 (pt) Processo de fabricação de uma prótese dentária e de um guia cirúrgico dentário.
NZ601148A (en) Use of pentosan polysulfate for treatment or prophylaxis of allergic rhinitis
MX2014004862A (es) Formulaciones de polimero acrilico.
CL2008002368A1 (es) Uso de gaboxadol para preparar un medicamento util en el tratamiento de la depresion en pacientes que tienen uno o mas marcadores inflamatorios elevados o anormales.
NI200800256A (es) Forma galénica divisible que permite una liberacion modificada del principio activo
BRPI0710405B8 (pt) comprimido de racecadotril, processo de preparação de um comprimido de racecadotril e uso de racecadotril
CL2012003729A1 (es) Composicion farmaceutica oral que comprende monohidrato de monolactato de 4-amino-5-fluoro-3-[6-(4-metil-piperazin-1-il)-1h-bencimidazol-2-il]-1h-quinolin-2-ona, uno o mas rellenos, un desintegrante y un lubricante; proceso de preparacion de la composicion.
BRPI1012051A2 (pt) "composição para o cuidado oral, filme de matriz polimétrica, e métodos para preparar o filme, e para tratar uma doença ou condição da cavidade oral"
BR112012006103B8 (pt) dispositivo de implante e kit
CL2014000849A1 (es) Compuestos derivados de benzilindazoles sustituido, inhibidores de la quinasa bub1; procedimiento de fabricacion; composicion farmaceutica; combinacion farmaceutica; y su uso en el tratamiento de enfermedades hiperproliferativas.
BR112015021908A8 (pt) implante, método de realizar uma ostomia, e método de fabricar um implante
BR112015031417A8 (pt) forma de dosagem farmacêutica, composição farmacêutica, métodos para tratamento de um paciente com necessidade de cisteamina e para preparo de uma forma de dosagem
BR112015003050A2 (pt) coordenador de uma rede clínica de área corporal (mban) associada a um ou mais dispositivos da mban, método de alternação de coordenador, e, pelo menos um controlador

Legal Events

Date Code Title Description
B25D Requested change of name of applicant approved

Owner name: EVONIK CORPORATION (US)

B25K Entry of change of name and/or headquarter and transfer of application, patent and certificate of addition of invention: republication

Owner name: EVONIK CORPORATION (US)

B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]

Free format text: NOTIFICACAO DE ANUENCIA RELACIONADA COM O ART 229 DA LPI

B06T Formal requirements before examination [chapter 6.20 patent gazette]
B09A Decision: intention to grant [chapter 9.1 patent gazette]
B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]

Free format text: PRAZO DE VALIDADE: 10 (DEZ) ANOS CONTADOS A PARTIR DE 27/10/2020, OBSERVADAS AS CONDICOES LEGAIS.

B16C Correction of notification of the grant [chapter 16.3 patent gazette]

Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 16/09/2010 OBSERVADAS AS CONDICOES LEGAIS. PATENTE CONCEDIDA CONFORME ADI 5.529/DF

B25G Requested change of headquarter approved

Owner name: EVONIK CORPORATION (US)